Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-09-18
2007-09-18
Mondesi, Robert B. (Department: 1652)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000, C435S007100
Reexamination Certificate
active
10459030
ABSTRACT:
The invention relates to peptides having the general formula (I), or a salt or amide thereof, wherein R1and R2are either the same or different, wherein R1and R2are each selected from the group consisting of hydrogen and a saturated or unsaturated hydrocarbon residue, said residue having from 1 to 10 carbon atoms, wherein Z1is selected from the group consisting of histidine and proline, wherein Z2is selected from the group consisting of an arginine and a peptide comprising an initial arginine and having from 2 to 30 amino acids. The invention also relates to methods using the peptides of the present invention in the treatment of inflammation
REFERENCES:
patent: 4927916 (1990-05-01), Matsueda et al.
patent: 5720934 (1998-02-01), Dean et al.
patent: 2003/0078613 (2003-04-01), Heidner
patent: 19729591 (1999-02-01), None
patent: WO/1993/21962 (1993-11-01), None
patent: WO/2002/048180 (2002-06-01), None
Herrick, S. et al. (2002). Role of Plasminogen Activators in Peritoneal Adhesion Formation. Biochem Soc Trans. Apr. 2002; 30(2):126-31.
Everse, S. J. (1999). Conformational Changes in Fragments D and Double-D from Human Fibrin(ogen) Upon Binding the Petide Ligand Gly-His-Arg-Pro-Amide. Biochemistry, Bd, 38, 18, 2941-2946.
Kunstfield et al. (1997) HECA-452 T Cells Migrate Through Superficial Vascular Plexus But Not Through Deep Vascular Plexus Endothelium, J Invest Dermatol. Mar. 1997;108(3):343-8.
Petzelbauer et al. (1996). Human Delayed-Type Hypersensitivity Reaction in a SCID Mouse Engrafted with Human T-Cells and Autologous Skin, J. Invest. Dermatol., 1996, 107: 576-581.
Kawasaki, K. (1989). Amino Acids and Peptides XII: Synthetic Peptides Related to the N-Terminal Portion of Fibrin Alpha-chain and their Inhibitory Effects on Fibrinogen/Thrombin Clotting. Thrombosis Research, Bd, 56: 757-762.
Skogen, W. F. et al. (1988). Fibrogen-Derived Peptide B 1-42 Is a Multidomained Neutrophil Chemoattractant. Blood 71: 1475-1479.
Henschen et al. (1985). High Performance Liquid Chromotography VCH.
Engelhart et al. (1984). Surveilance For Nonsocialcomical Infections and Fever of Unknown Origin Among Adult Heotology-Oncology Patients. Infect Control Hosp Epidemiol. May 2002;23(5):244-8.
Ikematsu. (1984). Radioimmunoassay of Fibrinopeptide, Bd. 28, Nr 1, 20-24, Table 2.
Harenberg, J. (1983). Biodistribution of Human Fibrinogen-derived Peptides in Rabbits. Fibrinogen: Struct. Variants Interact., 271-278.
Nieuwenhuizen et al. (1983), Biochem Biophys Acta, entitled Plasminogen activation by tissue activator is accelerated in the presence of fibrin(ogen) cyanoger bromide fragment FCB-2, 755: 531-533.
Nuzzo et al. (1981), Thermal Decomposition of Di(cycloalkyl)bi(triethylphosphine)platinum(II) Complexes. J. Amer. Chem. Soc., 37: 3404-3409.
Blomback et al. (1968). N-Terminal Disulphide Knot of Human Fibrinogen. Nature, 218: 130-134.
Merrifield, R. B. (1963). Solid Phase Peptide Synthesis. J. Amer. Chem. Soc., 85: 2149-2154.
Baker & Botts L.L.P.
Fibrex Medical Research & Development GmbH
Mondesi Robert B.
LandOfFree
Therapeutic fibrin-derived peptides and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic fibrin-derived peptides and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic fibrin-derived peptides and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3754518